LUND, Sweden and PALO ALTO, Calif., June 18, 2018 /PRNewswire/ — NeuroVive Pharmaceutical AB and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under NeuroVive’s NVP015 program….

Source: https://www.prnewswire.com/news-releases/neurovive-out-licenses-targeted-lhon-therapy-to-bridgebio-pharmas-new-subsidiary-fortify-therapeutics-300667278.html

This entry was posted on Monday, June 18th, 2018 at 1:30 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.